Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples